Novo Nordisk settles securities lawsuit in Denmark

A lawsuit concerning alleged market manipulation on the US insulin market has come to a settlement between plaintiffs, shareholders in Novo Nordisk, and the company.
Photo: Niels Hougaard/ERH
Photo: Niels Hougaard/ERH
by VICTOR EMIL KRISTENSEN, translated by daniel pedersen

Danish pharmaceutical firm Novo Nordisk has settled a 2019 lawsuit concerning an allegation that shareholders had been misled about insulin sales in the US, the company announces in a press release.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading